Trial Profile
A Phase I Single Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 29 Jul 2014
Price :
$35
*
At a glance
- Drugs Sibrotuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 29 Jul 2014 New trial record